AGIOS PHARMACEUTICALS, INC.
About AGIOS PHARMACEUTICALS, INC.
Agios Pharmaceuticals, Inc. is focused on discovering and developing novel drugs to treat cancer and rare genetic disorders of metabolism through scientific leadership in cellular metabolism. The company maintains an active research and discovery pipeline across both therapeutic areas with multiple first-in-class lead investigational medicines in clinical development. It is a public company traded on NASDAQ under AGIO and headquartered in Cambridge, Massachusetts.
- 🔗 Agios Pharmaceuticals Announces Pricing of $220 Million Public Offering of Common Stock – Agios Pharmaceuticals, Inc.
- 🔗 Agios Pharmaceuticals - 2026 Company Profile, Funding, Competitors & Financials - Tracxn
- 🔗 Agios Pharmaceuticals - 2026 Company Profile, Funding, Competitors & Financials - Tracxn
- 🔗 Here is What Hedge Funds Think About Agios Pharmaceuticals Inc (AGIO)
- 🔗 Agios Pharmaceuticals - Wikipedia
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Completed $220M public offering of common stock in December 2014.
- Raised $250M via stock offering in April 2017 to support cancer drug development.
- Total venture funding reached $120M across 6 rounds with 8 institutional investors.
- Filed NDA for ivosidenib in December 2017 for IDH1-mutated AML.
Ask StreetZero about AGIOS PHARMACEUTICALS, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account